Premium
Hydroxyapatite‐reinforced in situ forming PLGA systems for intraosseous injection
Author(s) -
Fisher Paul D.,
Venugopal Ganesh,
Milbrandt Todd A.,
Hilt J. Zach,
Puleo David A.
Publication year - 2015
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.35375
Subject(s) - plga , materials science , in situ , biomedical engineering , drug delivery , compressive strength , scaffold , ex vivo , composite material , porosity , glycolic acid , nanoparticle , in vivo , lactic acid , nanotechnology , chemistry , organic chemistry , medicine , genetics , microbiology and biotechnology , bacteria , biology
In situ forming poly(lactic‐ co ‐glycolic acid) (PLGA) implants have not been strongly considered for bone applications because of their poor mechanical properties. Here, in situ forming scaffolds containing hydroxyapatite micro‐ and nanoparticles were characterized to determine their mechanical properties, injectability, and microarchitecture. Scaffolds were prepared with various concentrations of hydroxyapatite, as well as poly(β‐amino ester) microparticles that facilitate drug delivery. Strength was increased threefold, from 2 to 6 MPa, while compressive modulus was improved sixfold, from 24 to 141 MPa, via the addition of 30% nanohydroxyapatite, which provided greater benefits at equivalent concentrations compared to micro‐hydroxyapatite. Scaffolds retained a uniformly porous microarchitecture, and hydroxyapatite particles were distributed evenly throughout the PLGA phase. Injectability, determined by the force required to inject 0.5 mL of material within 60 s, remained clinically acceptable at <50 N at 30% w/w hydroxyapatite and up to 10% w/w PBAE microparticles. Ex vivo injections into intact porcine femoral heads increased compressive modulus of trabecular bone from 81 to 180 MPa and strength from 3.5 to 5.9 MPa. This injectable scaffold offers mechanical reinforcement coupled with previously demonstrated drug delivery potential in a single injection for bone‐weakening conditions, such as osteonecrosis or osteoporosis. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103: 2365–2373, 2015.